IL6 and Cowden syndrome 1: One ongoing study will assess the effects of the IL-6 monoclonal antibody tocilizumab on the development of CS after MI (ClinicalTrials.gov Identifier: NCT05350592), testing the importance of inflammation and the neurohormonal response to the development of CS.